The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells
Introduction
Multidrug resistance (MDR) is a major obstacle for successful chemotherapy treatment, MDR is often the result of overexpression of a 170 kD plasma membrane glycoprotein known as P-glycoprotein (P-gp). P-gp belongs to the superfamily of adenosine triphosphate (ATP)-binding cassette (ABC) transporters and actively pumps out a wide range of structurally and functionally diverse amphipathic anticancer drugs from the inside of tumour cells thereby decreasing their intracellular accumulation [1]. Recent studies showed that tumour cells expressing MDR-associated protein (MRP), lung resistant protein (LRP) and mutation of DNA topoisomerase II are likely to be MDR 2, 3.
A plethora of agents are able to reverse the MDR phenotype in vitro4, 5, 6. Many natural and synthetic products of various structures, including calcium channel blockers (e.g. verapamil, nifedipine), calmodulin antagonists (e.g. trifluoperazine, chlorpromazine), quinolines (e.g. chloroquine, quinidine), immunosuppressive drugs (e.g. cyclosporin A, rapamycin) and yohimbine alkoids (e.g. reserpine, yohimbine) have been shown to partly or competitively inhibit the function of P-gp.
In vivo, combined therapy with MDR-related cytotoxins and modulators could shrink tumours and prolong the life-span in animal models. Unfortunately, the data regarding clinical efficacy are not yet available from the early clinical trials. Moreover, the MDR reversal agent may expose the patient to unacceptable side-effects or toxicity at the doses required for effectiveness and/or affect the pharmacokinetics of the anticancer drug 1, 7. These limitations have spurred on efforts to search for new, more effective compounds. New drugs developed specifically to inhibit P-gp and modulate MDR are currently one of the most important strategies in the field of cancer chemotherapy.
Tetrandrine (Tet), one of the bisbenzylisoquinoline alkaloids, has been used as an antifibrotic drug to treat the lesions of silicosis in China since the 1960s. It is relatively non-toxic to humans, even at the administration of 180 mg, intramuscularly (i.m.) three times daily (t.i.d.) [8]. Our previous studies showed Tet was able to reverse MDR in vitro[9]. The aim of this study was to determine whether Tet can enhance the efficacy of doxorubicin (Dox), both in vitro and in nude mice bearing tumours, and to probe the mechanism of the reversal of MDR.
Section snippets
Materials
Tet was generously provided by Dr Pan XP (Kuming Institute of Botany, Chinese Academy of Sciences). The powder of Tet, C38H42O6N2, with a purity of >98% was obtained by chromatography. Tet was freshly made before use. Fura 2-AM, Fura 2, 1,6-diphenyl-1,3,5-hexatriene (DPH) and Dox were purchased from Sigma Chemical Co. Dulbecco's modified Eagle's medium (DMEM) was purchased from Gibco BRL.
Cell lines and cell culture
The MDR cell lines MCF-7/adr and the parental sensitive cell line MCF-7 were generously provided by Prof.
Tet itself inhibits cell growth in the MCF-7 and MCF-7/adr cells
The cytotoxic effect of Tet after a 72-h treatment is shown in Fig. 1. The IC50 of Tet to MCF-7 and MCF-7/adr cells was 9.3±1.7 and 11.5±2.4 μmol/l, respectively. Cell survival was more than 90% in both the MCF-7/adr cells and their parental sensitive MCF-7 cells using Tet concentrations of ⩽2.5 μmol/l. So Tet concentrations of 2.5, 1.25, 0.625 μmol/l were used to study the reversal of MDR.
Reversal of MDR in vitro by Tet
The cells were incubated with various concentrations of Tet and a full range of concentrations of the
Discussion
Simultaneous genetic knockout of mdr1a and mdr1b resulted in healthy mice, indicating that P-gp is not essential for basic physiological functions [16]. This suggested that the combination of anticancer drugs with a non-toxic and potent P-gp inhibitor may be a promising approach to solve the problem of resistance. A large number of compounds, such as verapamil and cyclosporin A, can reverse the MDR phenotype mediated by P-gp in vitro17, 18. However, these agents are relatively weak P-gp
Acknowledgements
This work was supported in part by 990B82 Key Science and Technology Project Research Grant of Guangdong Province, China and No. 9800182, natural science foundation of Guangdong province, China and No. 9905 Excellent Youth Grant of the Ministry of Health of China.
References (25)
- et al.
Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
Semin. Cancer Biol.
(1997) - et al.
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
Eur. J. Pharm. Sci.
(2000) - et al.
Effects of ethanol on lateral and rotational mobility of plasma membrane vesicles isolated from cultured mouse myeloma cell line Sp2/0-Ag14
Biochim. Biophys. Acta
(1996) - et al.
Pharmacological characterization of LY335979a potent cyclopropyldibenzosuberane modulator of P-glycoprotein
Adv. Enzyme Regul.
(1997) Multidrug resistancemolecular mechanisms and clinical relevance
Cancer Chemother. Pharmacol.
(1997)Multidrug resistance and its reversal
Anticancer Res.
(1998)- et al.
Multidrug resistance transporters and modulation
Curr. Opin. Oncol.
(2000) - et al.
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Cancer Chemother. Pharmacol.
(1997) - et al.
ABC drug transportershereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2
Pharmacogenomics
(2001) - et al.
Tetrandinepharmacology and clinical usefulness
Chin. Pharmaceutic. J.
(1996)